tropicalmed-06-00155-v2.pdf (3.28 MB)
Cross-neutralisation of novel Bombali virus by Ebola virus antibodies and convalescent plasma using an optimised pseudotype-based neutralisation assay
journal contribution
posted on 2023-06-10, 02:17 authored by Emma M Bentley, Samuel Richardson, Maria Derveni, Pramila Rijal, Alain R Townsend, Jonathan L Heeney, Giada Mattiuzzo, Edward WrightEdward WrightEbolaviruses continue to pose a significant outbreak threat, and while Ebola virus (EBOV)- specific vaccines and antivirals have been licensed, efforts to develop candidates offering broad species cross-protection are continuing. The use of pseudotyped virus in place of live virus is recognised as an alternative, safer, high-throughput platform to evaluate anti-ebolavirus antibodies towards their development, yet it requires optimisation. Here, we have shown that the target cell line impacts neutralisation assay results and cannot be selected purely based on permissiveness. In expanding the platform to incorporate each of the ebolavirus species envelope glycoprotein, allowing a comprehensive assessment of cross-neutralisation, we found that the recently discovered Bombali virus has a point mutation in the receptor-binding domain which prevents entry into a hamster cell line and, importantly, shows that this virus can be cross-neutralised by EBOV antibodies and convalescent plasma.
History
Publication status
- Published
File Version
- Published version
Journal
Tropical Medicine and Infectious DiseaseISSN
2414-6366Publisher
MDPIExternal DOI
Issue
3Volume
6Page range
1-12Article number
a155Event location
SwitzerlandDepartment affiliated with
- Biochemistry Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2022-01-14First Open Access (FOA) Date
2022-01-14First Compliant Deposit (FCD) Date
2022-01-14Usage metrics
Categories
No categories selectedLicence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC